In the new round of drug price adjustment strategies based on price cuts, some of the tightest ischemic liquid products have seen a significant increase in retail prices. The imbalance in supply and demand of blood products will become the most critical factor in the price trend of products.
The major price increases include static propylene, human coagulation factor VIII (factor 8), and human fibrinogen, which are extremely tight products in the early market. At present, with the increase in the amount of pulp to keep up with the increase in demand for use and the gradual adjustment of the use structure of domestic blood products, the supply of such products as static and intravenous injections of hepatitis B in the future will continue to be tight and prices will rise. The potential is still there.
Shortage of product price increases <br> <br> latest round of national health insurance policy of drug price adjustment, the biggest bright spot is part of the scarce varieties of price increases, especially blood products price increase.
Specific specifications, intravenous injection of human immunoglobulin injection (static propylene) 1g, 5g, 10g three specifications have a substantial increase, of which 10g product prices from 1050 yuan each to 1616 yuan each, an increase of up to 53.9%; 200IU and 300IU of eight-factor injection prices are basically doubled, 200IU product prices increased from 194.12 yuan to 396 yuan each, an increase of 104.00%; 0.5g human fibrinogen injection price increased from 147 yuan to 350 yuan each The increase reached 138.1%.
The most direct stimulating factors for the price increase of these varieties are the serious shortages of these varieties nationwide in the past one year or more. This has aroused the attention of the people and relevant responsible persons of the country.
For example, clotting factors, nearly one-quarter of hemophilia patients in the world in China, and hemophilia is a lifelong disease, infusion of eight factors is currently the only effective treatment. According to data from the Chinese Blood Friends' Home, there are 100,000 to 130,000 people with hemophilia in China. Patients with moderate hemophilia need at least 10 factors (200 units) per month, and 24,000 units of products are needed each year. According to the 10% visit rate, it is estimated that the annual demand for eight factors is about 240 million units. In 2011, the eight-factor batch was issued for 350,000 bottles, estimated at 300IU per bottle, which is about 105 million units, and the gap is extremely large.
The price increase of some products is partly due to the country’s desire to encourage companies to use R&D to produce a shortage of products through price levers. On the other hand, it also reflects that blood products are life-saving drugs, and its supply stability needs to be guaranteed. Market shortages form a pricing model for the country. Forced. It also means that despite the pricing of blood products countries, the imbalance between supply and demand has a great influence on the country's pricing strategy.
Follow-up is still room <br> <br> Overall, blood products in the future there is still much room for growth in the price, the main one is judged based on the current annual growth rate of domestic plasma collection station around 5%, far more than Not much of the growth rate of demand for most varieties; Second, the use of domestic blood product structure changes; Third, the expansion of indications for blood products.
It can be said that, in addition to human serum albumin, the vast majority of products issued in excess of one million in batches have room for growth. The premise is that the national plasma collection will not increase rapidly in the short term, and the country's blood product supervision policy will not abruptly change.
Human albumin has price pressure, mainly because it is the only blood product allowed by the country. Although the compound growth rate of batches issued in recent years has remained at more than 20%, the overall import product has grown faster, with an average annual rate of nearly 30%. growth of.
In 2011, the share of imported human albumin has accounted for more than 48%. The increase in imported goods was due to the fact that the international product price was only US$30/10g, the domestic product conversion was as high as US$60/ton, the importer’s power was sufficient, and there was no price to resist domestic consumption.
As far as existing domestic product varieties are concerned, the products that the industry prefers include human intravenous immunoglobulin, hepatitis B human immunoglobulin, and clotting factor-like small species.
At present, the consumption of albumin occupies the bulk of China's use of blood products. From the perspective of the use of blood products in developed countries and the growth rate of single blood products in China, the future use of blood products in China is under the general trend of overall growth. The proportion of albumin will continue to decline, and the proportion of use of static propylene will increase to exceed that of human albumin. The proportion of clotting factors used will also gradually increase, and this trend is already emerging.
For example, static C, despite the current round of drug price adjustment, the regular retail price of 2.5 g/bottle of Jing Bing’s conventional dosage form is 561 yuan, which is reduced by about 10%. However, other specifications increase, and the future price space of the product is still worth expecting. . The main reason is that domestic per capita use of static propane is only about half of the world average per capita use, only about 10% of developed countries, the United States in the past 10 years, the use of basic C-ups. In addition, due to the constraints of national medical insurance, clinical use concepts, and understanding of products, the indication of domestic static propylene is also much smaller than that of foreign countries, and the approval of FDA for the use of blood products is constantly magnified. This will also be the future of the country. trend.
However, the current domestic demand for static C-propylene products has grown significantly. The average growth rate in previous years exceeded 10%, and the number of batches issued in the same period in 2011 increased by 28%, indicating that the clinical needs and concept of use are gradually changing.
In terms of price, foreign 300-400 US dollars / 5g, the domestic is only 1140 yuan / 5g, the domestic product is far lower than the international market price, a huge price gap can ensure that imported products have no import power.
Because imports are not allowed, the rate of slow recovery of domestic stocks can hardly catch up with the growth rate of the demand for static propylene. Therefore, the situation of shortage of static propylene will continue, and static propylene will have the conditions of rising prices and prices.
Bacteria is a rapid and reliable disinfection and sterilization equipment using pressure saturated steam, which is suitable for medical and health undertakings, scientific research, agriculture and other units. Sterilize medical equipment, dressings, glassware, solution cultures, etc. It is also suitable for high-quality drinking water produced by high-altitude food steaming equipment and enterprises and institutions, and can also be used as high-temperature steam source equipment.
The temperature of the steam in the autoclave is not only related to the pressure, but also related to the saturation of the steam. If the air in the autoclave is not exhausted or exhausted, the steam cannot reach saturation. Although the pounds expresses the sterilization pressure, the temperature of the steam does not reach the required height, resulting in failure of sterilization. The presence of air in the autoclave during sterilization can also affect the penetration of steam into the sterilized items. Saturated steam can penetrate into the center of the dressing bag. When the air is not completely eliminated, the temperature inside the bag is low and the temperature outside the bag is high, so that the inside cannot be sterilized.
The method to check whether the sterilizer air is exhausted is to connect a leather tube at the outlet of the exhaust pipe and insert the other end into the cold water basin. If the air discharged from the tube generates bubbles in the cold water, it means that it has not been exhausted. It still needs to continue to exhaust; if no bubbles are generated, it means that the cold air in the pot has been basically drained. If there is a certain amount of steam in the sterilizer before venting, it will help to drain the air.
vertical autoclave,horizontal autoclave,industrial autoclave
Suzhou Escomedical Equipment Co.,Ltd , https://www.escodental.com